US stocks: Fulcrum shares plummet over 50% after scrapping lead sickle-cell drug on FDA concerns

Fulcrum Therapeutics' decision to halt development of its sickle-cell drug due to FDA concerns triggered a massive stock selloff, signaling increased risk and uncertainty for investors in the company. This highlights the vulnerability of biotech firms to regulatory hurdles and the potential for significant losses when drug development fails to progress.